These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 14679938)
1. We want our Trizivir! Vázquez E Posit Aware; 2003; 14(5):25-6. PubMed ID: 14679938 [No Abstract] [Full Text] [Related]
2. Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir. TreatmentUpdate; 2004 Mar; 16(2):2-3. PubMed ID: 17219666 [No Abstract] [Full Text] [Related]
3. AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial. Gallant JE Hopkins HIV Rep; 2003 Jul; 15(4):1-2. PubMed ID: 14696559 [No Abstract] [Full Text] [Related]
4. Abandon Trizivir when it's working well? A rebuttal. Erbelding EJ Hopkins HIV Rep; 2003 Jul; 15(4):1. PubMed ID: 14696560 [No Abstract] [Full Text] [Related]
5. Long-term control of viral residual replication under maintenance therapy with Trizivir after a quadruple induction regimen in HIV-1-infected adults (Suburbs trial). de Truchis P; Mathez D; Force G; Rouveix E; Khuong MA; Chemlal K; Thiaux C; Leibowitch J HIV Clin Trials; 2007; 8(2):102-4. PubMed ID: 17507326 [No Abstract] [Full Text] [Related]
6. Abacavir arm stopped in clinical trial. James JS AIDS Treat News; 2003 Apr; (390):6-7. PubMed ID: 12739475 [TBL] [Abstract][Full Text] [Related]
7. Anti-HIV agents. Abacavir--as good as AZT? TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861 [No Abstract] [Full Text] [Related]
8. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis. Moyle GJ; Gazzard BG AIDS; 2002 May; 16(7):1086-7. PubMed ID: 11953482 [No Abstract] [Full Text] [Related]
9. [First HIV triple therapy with one tablet]. Dtsch Med Wochenschr; 2000 Feb; 125(8):A22. PubMed ID: 10723466 [No Abstract] [Full Text] [Related]
10. AIDS drug in halted trial less effective as monotherapy. AIDS Read; 2003 Apr; 13(4):159. PubMed ID: 12741364 [No Abstract] [Full Text] [Related]
11. Anatomy of a study: Trizivir vs. Sustiva. Berger DS Posit Aware; 2003; 14(3):40-1. PubMed ID: 12866492 [No Abstract] [Full Text] [Related]
12. Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095. Feinberg J AIDS Clin Care; 2006 Nov; 18(11):99. PubMed ID: 17183745 [No Abstract] [Full Text] [Related]
14. FDA notifications. Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets. AIDS Alert; 2009 Sep; 24(9):106. PubMed ID: 19928326 [No Abstract] [Full Text] [Related]
15. Top stories of 2004. ACTG 5095: efavirenz beats AZT + 3TC + abacavir. del Rio C AIDS Clin Care; 2005 Jan; 17(1):4. PubMed ID: 15717367 [No Abstract] [Full Text] [Related]
16. Abacavir sulfate, lamivudine, and zidovudine (Trizivir). Porche D J Assoc Nurses AIDS Care; 2001; 12(6):88-90. PubMed ID: 11723917 [TBL] [Abstract][Full Text] [Related]
17. Anti-HIV agents. Trizivir--three drugs in one pill. TreatmentUpdate; 2000 Feb; 12(1):1-2. PubMed ID: 12125625 [No Abstract] [Full Text] [Related]
18. FDA approves Trizivir for HIV infection. AIDS Read; 2000 Dec; 10(12):701. PubMed ID: 11189737 [No Abstract] [Full Text] [Related]
19. AIDS foundation seeks withdrawal of approval for HIV drug combination. Clarke B Lancet Infect Dis; 2003 Oct; 3(10):604. PubMed ID: 14558502 [No Abstract] [Full Text] [Related]
20. New formulations approved for children. AIDS Patient Care STDS; 2008 Jan; 22(1):88. PubMed ID: 18453043 [No Abstract] [Full Text] [Related] [Next] [New Search]